News | November 04, 2022
Sanofi India posts Q3CY22 net profit at Rs. 130.9 Cr
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
He has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited.
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
The team will also assist the state health departments in terms of public health measures, management guidelines and protocols to manage the increasing cases of Avian Influenza
The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
Subscribe To Our Newsletter & Stay Updated
